Director Douglas Wurth Buys $25,000 in Bluejay Diagnostics Stock
BJDX is trading near its 52-week low of $1.63 (9.8% above the low) on light trading volume (0.2× avg).
Summary
Bluejay Diagnostics Director Douglas Wurth purchased $25,000 worth of common stock in a private placement, signaling insider confidence amidst the company's financial challenges.
Key Events · Ownership and Investor Activity · BJDX
-
Director Stock Purchase
Director Douglas Wurth acquired 12,500 shares of common stock for $25,000 in a private placement on March 14, 2026, at a price of $2.00 per share.
-
Insider Confidence Signal
This purchase, representing 1.4% of the company's market capitalization, indicates insider confidence at a time when Bluejay Diagnostics faces a critical going concern warning and is seeking additional capital.
Analysis · BJDX · Industrial Applications And Services
Director Douglas Wurth's $25,000 purchase of common stock in a private placement is a positive signal of insider confidence, especially given Bluejay Diagnostics' recent going concern warning and need for capital. While the amount is modest in absolute terms, it represents a significant percentage of the company's small market capitalization, indicating a belief in the company's future despite its financial challenges.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 29.2% of the 1541 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BJDX was trading at $1.79 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $1.63 to $16.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.